NCT00810017View on ClinicalTrials.gov

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

June 30, 2010

Conditions
HER-2 Positive Metastatic Breast Cancer
Interventions
DRUG

Etoposide

etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles

DRUG

Trastuzumab

intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease

Trial Locations (1)

20010

Washington Cancer Institute, Washington D.C.

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Medstar Health Research Institute

OTHER